Alveolus Bio, a US-based respiratory drug development company, announced on Monday a strategic financing round led by India-based global pharmaceutical company Shilpa Medicare Limited (BSE:530549, NSE:SHILPAMED).

The investment is intended to support Alveolus Bio's advancement toward Phase 2 and first-in-human clinical trials with a therapeutic candidate targeting Chronic Obstructive Pulmonary Disease (COPD).

As part of the collaboration, Shilpa Biologics, the biologics division of Shilpa Medicare, will serve as Alveolus Bio's exclusive global development and manufacturing partner. The partnership leverages Shilpa's expertise in drug discovery, regulatory strategy, and manufacturing to scale Alveolus Bio's live biotherapeutics and small molecule platform.

The core focus is the resMIT platform - respiratory microbiota-based inhaled therapeutics - designed to deliver targeted treatments deep into the lungs. This approach aims to address critical unmet needs in COPD, Bronchopulmonary Dysplasia (BPD), and Pulmonary Fibrosis.

The funding round remains open to additional strategic investors aligned with Alveolus Bio's mission.